AJMC July 26, 2024
Doug Fulling, MA, president of Precision AQ, and Andrew Cournoyer, senior vice president and director of the access experience team at Precision AQ, spoke with The American Journal of Managed Care® about how introducing payers into clinical spaces earlier could improve pricing conversations with manufacturers.
This transcript has been lightly edited for clarity.
Transcript
Can the pricing conversations with manufacturers be affected by payers being introduced to clinical trials earlier?
Andrew Cournoyer: I do think there is some benefit when it comes to pricing. I mean, payers are looking at drug categories, whether it’s a new category that has no options or ones that are somewhat commoditized, and have a sense of what price to value looks like. I think...
Today's Sponsors
Today's Sponsor